A study of the changes in the cause of peptic ulcer bleeding

Haruka Fujinami, Takahiko Kudo, Ayumu Hosokawa, Kohei Ogawa, Takako Miyazaki, Jun Nishikawa, Shinya Kajiura, Takayuki Ando, Akira Ueda, Toshiro Sugiyama

Haruka Fujinami, Takahiko Kudo, Ayumu Hosokawa, Kouhei Ogawa, Takako Miyazaki, Jun Nishikawa, Shinya Kajiura, Takayuki Ando, Akira Ueda, Toshiro Sugiyama, Department of Gastroenterology, University of Toyama, 2630 Sugitani, Toyama 9300194, Japan

Author contributions: Fujinami H carried out the data analyses and drafted the manuscript; Kudo T, Hosokawa A, Ogawa K, Miyazaki T, Nishikawa J, Kajiura S, Ando T and Ueda A carried out endoscopic examinations of the study subjects and data collection; Sugiyama T revised the manuscript and supervised the work.

Correspondence to: Haruka Fujinami, MD, Assistant Professor of Medicine, Department of Gastroenterology, University of Toyama, 2630 Sugitani, Toyama 9300194, Japan. haruka52@med.u-toyama.ac.jp

Telephone: +81-76-4347301 Fax: +81-76-4345027

Received: August 19, 2011 Revised: February 2, 2012 Accepted: July 1, 2012 Published online: July 16, 2012

Abstract

AIM: To clarify the frequency of and changes in the cause of peptic ulcer bleeding.

METHODS: This study retrospectively evaluated the out- and inpatients who underwent endoscopy between 2002 to 2008. The subjects were patients presenting with peptic ulcer bleeding. The details of these patients were obtained from their endoscopic reports and medical records.

RESULTS: The rates of Helicobacter pylori (H. pylori) infection were significantly low (P = 0.039), while the proportion of nonsteroidal antiinflammatory drugs (NSAIDs) users and vascular disease significantly increased over the period studied (P = 0.034 and P = 0.04, respectively). However, there was no significant difference in the proportion of low-dose aspirin users (P = 0.832).

CONCLUSION: It’s found that the primary cause of peptic ulcer bleeding changed from H. pylori infection to use of NSAIDs over the 7-year period of study. It seems that the number of low-dose aspirin users has increased with the increase in the proportion of vascular disease. It is necessary to take measures to prevent peptic ulcer bleeding among NSAIDs and low dose aspirin users.

INTRODUCTION

Helicobacter pylori (H. pylori) infection and the use of nonsteroidal antiinflammatory drugs (NSAIDs) are two of the major risk factors for peptic ulcers and ulcer complications. H. pylori infection has been recognized in more than 87% of patients with gastric ulcers and about 96% of patients with duodenal ulcers. The incidence of peptic ulcers has steadily decreased in Western countries, and this decrease is thought to result from both the widespread eradication of H. pylori and the decreasing prevalence of H. pylori infection in the population as a result of the improvement in hygienic conditions.
On the other hand, the use of NSAIDs is associated with an increased risk of major upper gastrointestinal complications, including bleeding and perforation\[^{3-7}\]. With the increase in the elderly population, which has led to an increase in musculoskeletal and joint disorders, it seems that the consumption of NSAIDs has increased. In addition, antiplatelet therapy with low-dose aspirin (75-325 mg) reduces the risk of vascular events in patients with cardiovascular and cerebrovascular diseases\[^{8-10}\]. Although low-dose aspirin has the advantages of being both highly effective and inexpensive, they pose a significant risk for developing peptic ulcer bleeding\[^{11-13}\]. The aim of this study is to clarify the frequency and trends of peptic ulcer bleeding over the past seven years.

### MATERIALS AND METHODS

#### Patients

This study retrospectively evaluated the 199,994 of out- and inpatients who underwent endoscopy at Toyama University Hospital between January 2002 and December 2008. We collected the following details of patients with peptic ulcer bleeding from their endoscopic reports and medical records: age, gender, symptoms, *H. pylori* infection, NSAIDs intake, low-dose aspirin intake, previous ulcer history, cardiovascular and cerebrovascular diseases, endoscopic findings, and interventions. The rate of gastroduodenal ulcer (GDU) and peptic ulcer bleeding, average age, body proportions, hematemesis, melena, and previous ulcer histories, rate of *H. pylori* infection, rate of cardiovascular and cerebrovascular diseases and proportion of NSAIDs and low-dose aspirin users were calculated and compared from 2002 to 2008 based on this information. The subjects were checked for *H. pylori* infection using the \[^{13}C\]-urea breath test (UBT) and/or rapid urease test (RUT). *H. pylori* status was defined as *H. pylori*-negative when UBT was negative and *H. pylori*-positive when either UBT or RUT were positive. Peptic ulcer bleeding was defined as a clinical presentation of hematemesis and/or melena, and endoscopic examination showed a peptic gastric and/or duodenal ulcer. However, we also anticipated the presence of upper gastrointestinal tract neoplasm, erosive gastritis, erosive duodenitis, Mallory-Weiss syndrome, and esophagogastric varices.

#### Statistical analysis

The following details of peptic ulcer bleeding patients were obtained from their endoscopic reports and medical records: age, gender, symptoms, *H. pylori* status, NSAIDs intake, low-dose aspirin intake, previous ulcer history, endoscopic findings, and interventions. The rate of peptic ulcer and/or peptic ulcer bleeding, average age, body proportions, hematemesis, melena, previous ulcer histories, rate of *H. pylori* infection, rate of cardiovascular and cerebrovascular diseases and rate of NSAIDs, low-dose aspirin users were calculated and compared from 2002 to 2008 based on this information.

Changes in each parameter over the period studied were analyzed using the chi-square test. Differences were considered to be statistically significant when *P* < 0.05.

### RESULTS

The details of subjects were showed in Table 1. The rate of GDU decreased from 16.9% to 11.3% over the period studied, and there were significant changes (*P* < 0.001). The rate of peptic ulcer bleeding significantly increased from 4.87% to 9.03% during the first three years (*P* < 0.001) and significantly decreased from 9.03% to 5.95% during the last three years (*P* < 0.05). The clinical details of those patients who presented with peptic ulcer bleeding are shown in Table 2. Age and gender did not change significantly over the period studied. The rate of GDU decreased. Cardiovascular and cerebrovascular diseases significantly increased from 29.2% to 61.9% over the period studied (*P* = 0.04). The risk factors of peptic ulcer bleeding are shown in Table 3. *H. pylori* infection rate was 84.2% in 2002, 72.6% in 2005, and 71.4% in 2008, which demonstrates a significant decrease (*P* = 0.048). The greatest cause of peptic ulcer bleeding was the use of gastrointestinal injury drugs, such as NSAIDs and low-dose aspirin. The proportion of NSAIDs users significantly increased (*P* = 0.034), but there were no significant changes in the proportion of low-dose aspirin users (*P* = 0.832). The proportion of NSAIDs (including low-dose aspirin) users significantly increased over the period studied (*P* = 0.021).

### DISCUSSION

In this study, it was found that the number of peptic ulcer bleeding cases significantly increased during the first three years. One explanation for this is that while the *H. pylori* infection rate decreased over this period, the main cause of peptic ulcer bleeding changed from *H. pylori* infection to use of NSAIDs, including low-dose aspirin. NSAIDs were associated with approximately 30% of the bleeding peptic ulcers diagnosed in Japan, which shows a significant increase from the figures of previous reports. One reason of the increased number of NSAIDs users is that it is used in treating back and joint pain, which has shown an increased incidence among the increasing elderly population\[^{14,15}\]. In the United States, hospitalization and death due to NSAID-related gastrointestinal events have been estimated at 103,000 and 16,500 patients per year, respectively\[^{16}\]. In a population-based retrospective case-control study, the adjusted relative risk (RR) of upper gastrointestinal bleeding (UGIB) associated with NSAIDs use was 5.3 [95% confidence interval (CI): 4.5-6.2]\[^{17}\]. In our study, NSAIDs use was significantly associated with an increased risk of bleeding ulcer, and the rate of *H. pylori* infection was significantly lower throughout the observed period. Nonetheless, the number of peptic ulcer bleeding was decreased during the last three years. As one of the possibilities, a
Recently it was suggested that the damaging effect of low-dose aspirin users will increase in the future because it reduces the risk of cardiovascular events and anti-coagulants, and corticosteroids seemed to be factors associating drug use with UGIB were 1.8 (1.5-2.1) for low-dose aspirin, 1.1 (0.6-2.1) for clopidogrel, 1.9 (1.3-2.8) for dipyridamole, 1.8 (1.3-2.4) for vitamin K antagonists, 7.4 (3.5-15) for clopidogrel and aspirin, 5.3 (2.9-9.5) for vitamin K antagonists and aspirin, and 2.3 (1.7-3.3) for dipyridamole and aspirin. These results suggest that combined antithrombotic therapy with low-dose aspirin is associated with an increased risk of UGIB. We also found that the proportion of NSAIDs and low-dose aspirin users was significantly increasing over the period studied. The odds ratio of a combination of NSAIDs and low-dose aspirin was reported as 12.7 (95% CI: 7.0-23.0). Furthermore, the concurrent use of non-aspirin antiplatelet agents with traditional NSAIDs also potentiated the risk of UGIB. In a meta-analysis of randomized, placebo-controlled trials of low-dose aspirin, prior gastrointestinal events, older age, and the use of other injurious medications, such as NSAIDs, anticoagulants, and corticosteroids seemed to be factors associated with an increased risk for UGIB.

In the future, it will be necessary to prevent the association between UGIB and the use of NSAIDs and low-dose aspirin because it is expected that the more the proportion of the elderly population increases, the more coexisting diseases, such as cardiovascular disease, cerebrovascular disease, and musculoskeletal disorders will increase. The use of both NSAIDs for the treatment of musculoskeletal pain and low-dose aspirin as an anti-thrombotic therapy has increased recently. This tendency has been deduced from our data, which reveals that cardiovascular and cerebrovascular diseases have increased in recent years. However, the use of aspirin, even at a low dose for secondary prevention of cardiovascular events, remains a risk factor for developing UGIB. In addition, more than a few epidemiological studies have suggested that *H. pylori* infection increases the risk of UGIB in patients taking low-dose aspirin. Taha et al. reported that the increase in UGIB associated with the use of gastrointestinal toxic drugs increased in subjects treated with low-dose aspirin between 1996 and 2002. A recent study indicates that the relative risk of UGIB after exposure to low-dose aspirin is 3.7 (95% CI: 3.0-4.5). In our study, we found that the proportion of low-dose aspirin users also increased from 8.3% in 2002 to 14.3% in 2008. In addition, our data showed the significant increasing of cardiovascular and cerebrovascular diseases. Therefore, the proportion of low-dose aspirin users will be increased in future. Recently it was suggested that the damaging effect of aspirin alone on the gastric mucosa might be less potent than the effect of NSAIDs. In a case-control study by Hallas et al., the age- and sex-adjusted odds ratios associating drug use with UGIB were 1.8 (1.5-2.1) for low-dose aspirin, 1.1 (0.6-2.1) for clopidogrel, 1.9 (1.3-2.8) for dipyridamole, 1.8 (1.3-2.4) for vitamin K antagonists, 7.4 (3.5-15) for clopidogrel and aspirin, 5.3 (2.9-9.5) for vitamin K antagonists and aspirin, and 2.3 (1.7-3.3) for dipyridamole and aspirin. These results suggest that combined antithrombotic therapy with low-dose aspirin is associated with an increased risk of UGIB. We also found that the proportion of NSAIDs and low-dose aspirin users was significantly increasing over the period studied. The odds ratio of a combination of NSAIDs and low-dose aspirin was reported as 12.7 (95% CI: 7.0-23.0). Furthermore, the concurrent use of non-aspirin antiplatelet agents with traditional NSAIDs also potentiated the risk of UGIB. In a meta-analysis of randomized, placebo-controlled trials of low-dose aspirin, prior gastrointestinal events, older age, and the use of other injurious medications, such as NSAIDs, anticoagulants, and corticosteroids seemed to be factors associated with an increased risk for UGIB.

In the future, it will be necessary to prevent the association between UGIB and the use of NSAIDs and low-dose aspirin because it is expected that the more the proportion of the elderly population increases, the more coexisting diseases, such as cardiovascular disease, cerebrovascular disease, and musculoskeletal disorders will increase. The use of both NSAIDs for the treatment of musculoskeletal pain and low-dose aspirin as an anti-thrombotic therapy has increased recently. This tendency has been deduced from our data, which reveals that cardiovascular and cerebrovascular diseases have increased in recent years. However, the use of aspirin, even at a low dose for secondary prevention of cardiovascular events, remains a risk factor for developing UGIB. In addition, more than a few epidemiological studies have suggested that *H. pylori* infection increases the risk of UGIB in patients taking low-dose aspirin. Taha et al. reported that the increase in UGIB associated with the use of gastrointestinal toxic drugs increased in subjects treated with low-dose aspirin between 1996 and 2002. A recent study indicates that the relative risk of UGIB after exposure to low-dose aspirin is 3.7 (95% CI: 3.0-4.5). In our study, we found that the proportion of low-dose aspirin users also increased from 8.3% in 2002 to 14.3% in 2008. In addition, our data showed the significant increasing of cardiovascular and cerebrovascular diseases. Therefore, the proportion of low-dose aspirin users will be increased in future. Recently it was suggested that the damaging effect of aspirin alone on the gastric mucosa might be less potent than the effect of NSAIDs. In a case-control study by Hallas et al., the age- and sex-adjusted odds ratios associating drug use with UGIB were 1.8 (1.5-2.1) for low-dose aspirin, 1.1 (0.6-2.1) for clopidogrel, 1.9 (1.3-2.8) for dipyridamole, 1.8 (1.3-2.4) for vitamin K antagonists, 7.4 (3.5-15) for clopidogrel and aspirin, 5.3 (2.9-9.5) for vitamin K antagonists and aspirin, and 2.3 (1.7-3.3) for dipyridamole and aspirin. These results suggest that combined antithrombotic therapy with low-dose aspirin is associated with an increased risk of UGIB. We also found that the proportion of NSAIDs and low-dose aspirin users was significantly increasing over the period studied. The odds ratio of a combination of NSAIDs and low-dose aspirin was reported as 12.7 (95% CI: 7.0-23.0). Furthermore, the concurrent use of non-aspirin antiplatelet agents with traditional NSAIDs also potentiated the risk of UGIB. In a meta-analysis of randomized, placebo-controlled trials of low-dose aspirin, prior gastrointestinal events, older age, and the use of other injurious medications, such as NSAIDs, anticoagulants, and corticosteroids seemed to be factors associated with an increased risk for UGIB.
Pignone M, Phillips C, Mulrow C. Aspirin for peptic ulcer bleeding

The prevention of peptic ulcers related to the use of NSAIDs and/or low-dose aspirin will become an important issue in the future. It is suggested that those patients who need NSAIDs treatment use the prostaglandin analogue misoprostol[39] or acid-suppressive agents, such as high-dose H$_2$ receptor antagonists[36] and PPI[31]. Switching from non-selective NSAIDs to cyclooxygenase-2 inhibitors[12] is also a choice. In the prevention of ulcers caused by NSAIDs and/or low-dose aspirin, the effectiveness of H. pylori eradication therapy has been reported[13]. In naive NSAIDs users, it has been suggested to receive H. pylori eradication therapy before NSAIDs use. A similar strategy has also been suggested for naive aspirin users[34]. In chronic NSAIDs/aspirin users, the recommendations may depend on the risk for peptic ulcer complications. Those who continue taking NSAIDs/aspirin, being at high-risk for peptic ulcer complication, should be tested for the presence of H. pylori infection and, if positive, receive H. pylori eradication therapy, as well as long-term therapy with a PPI[35,37].

Where the elderly population is increasing, it seems likely that the consumption of NSAIDs and low-dose aspirin will also increase in the future. Therefore, it is necessary to make guidelines for the use of NSAIDs and low-dose aspirin with the cooperation of gastroenterologists, neurologists, cardiologists, and orthopedic surgeons.

Peer review

This paper describes the rate of peptic ulcer bleeding and the change in the causes of this. Although H. pylori infection and the use of NSAIDs were adopted as a risk factor, it was indicated that other factors (i.e., corticosteroid, warfarin and clopidogrel) should also have been examined. Though we find that frequency on gastrointestinal bleeding has been subsequently decreasing recent years, it was reported that the increase in the usage of PPI is related. To investigate the cause by which the peptic ulcer bleeding is decreased will be desired from now on.

REFERENCES

1. Kurata JH, Nagawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997; 24: 2-17
2. Arroyo MT, Forne M, de Argila CM, Feu F, Arenas J, de la Vega J, Garrigues V, Mora F, Castro M, Bujanda L, Cosme A, Castiella A, Gisbert JP, Hervas A, Lasas A. The prevalence of peptic ulcer not related to Helicobacter pylori or non-steroidal anti-inflammatory drug use is negligible in southern Europe. Helicobacter 2004; 9: 249-254
3. Personon J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9 Suppl 2: 45-51
4. Roosendaal R, Kuipers EJ, Buitenwerf J, van Uffelen C, Meuwissen SG, van Kamp GJ, Vandenbroucke-Grauls CM. Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 1997; 92: 1480-1482
5. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-2099
6. Langman MJ. Epidemiology of non-steroidal anti-inflammatory drug damage to stomach and duodenum. Ital J Gastroenterol Hepatol 1999; 31 Suppl 1: S2-S5
7. Langman MJ. Adverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tract. Fundam Clin Pharmacol 2003; 17: 393-403
8. Antiplatelet Trialsists’ Collaboration. Collaborative overview of randomised trials of antplatelet therapy--II: Maintenance of vascular graft or arterial patency by antplatelet therapy. Antiplatelet Trialsists’ Collaboration. BMJ 1994; 308: 159-168
9. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161-172
10. Antithrombotic Trialsists’ Collaboration. Collaborative meta-analysis of randomised trials of antplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
11. Kelly JP, Kaufman DW, Jurgenon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413-1416
12. Lasas A, Bajador E, Serrano F, Fuentes J, Carreño S, Guarra D, Sanz M, Monotoro M, Sáinz R. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834-839
13. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin - what’s the risk? Aliment Pharmacol Ther 2006; 24: 897-908
14. Nakashima S, Arii S, Mizuno Y, Yoshino K, Ando S, Nakamura Y, Sugawara K, Koike M, Saito E, Naito M, Nakao M, Ito H, Hamaoka K, Rai F, Asakura Y, Akamatu M, Fujimori K, Inao M, Imai Y, Ota S, Fujiwara K, Shibishi M. A clinical study of Japanese patients with ulcer induced by low-dose

COMMENTS

Background

Helicobacter pylori (H. pylori) infection and non-steroidal anti-inflammatory drugs (NSAIDs) including low dose aspirin are two of the major risk factors for peptic ulcers. With the increase in the elderly population, which has led to an increase in musculoskeletal and joint disorders, ischemic heart disease and cerebrovascular disease, it seems that the incidence of NSAID-related peptic ulcer has increased. The aim of this study is to clarify the frequency and trends of peptic ulcer bleeding over the studied period.

Research frontiers

In Western countries, H. pylori infection rate is low and the cause of peptic ulcer was NSAIDs. Since the same tendency was recognized in Japan, it is necessary to investigate about changes in the cause of peptic ulcer.

Innovations and breakthroughs

In this study, it was found that the number of peptic ulcer bleeding case was increased and H. pylori infection rate was decreased over the studied period, the main cause of peptic ulcer bleeding changed from H. pylori infection to use of NSAIDs, including low-dose aspirin.

Applications

In fact that gastroesophageal reflux disease is increasing and the usage of proton pump inhibitors (PPI) is actually increasing in Japan. The results suggest that peptic ulcer will be decreased in the future.

Terminology

Peptic ulcer bleeding: Defined as a clinical presentation of hematemesis and/or melena, and endoscopic examination showed a peptic gastric and/or duodenal ulcer bleeding.
aspirin and other non-steroidal anti-inflammatory drugs. *Aliment Pharmacol Ther* 2005; 21 Suppl 2: 60-66
15 Ootani H, Iwakiri R, Shimoda R, Nakahara S, Amemori S, Fujise T, Kikkawa A, Tsunada S, Sakata H, Fujimoto K. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers in Japan. *J Gastroenterol* 2006; 41: 41-46
16 Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. *N Engl J Med* 1999; 340: 1888-1899
17 Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A, Zapata E, Bástad G, Rodrigo L, Santolaria S, Güell M, de Argila CM, Quintero E, Borda F, Piqué JM. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. *Gut* 2006; 55: 1731-1738
18 Hermansson M, Ekedahl A, Ranstam J, Zilling T. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002. *BMJ Gastroenterol* 2009; 9: 25
19 Fujisawa Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. *J Gastroenterol* 2000; 35: 518-544
20 Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. *Aliment Pharmacol Ther* 2002; 16: 497-506
21 Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sáinz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. *Aliment Pharmacol Ther* 2002; 16: 779-786
22 Taha AS, Angerson WJ, Knill-Jones RP, Blatchford O. Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs - a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. *Aliment Pharmacol Ther* 2005; 22: 285-289
23 Singh G, Ramey DR, Morfeld D, Fries JF. Comparative toxicity of non-steroidal anti-inflammatory agents. *Pharmacol Ther* 1994; 62: 175-191
24 Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, Andersen M, Lassen AT. Use of single and combined anti-thrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. *BMJ* 2006; 333: 726
25 Shiotani A, Kamada T, Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. *J Gastroenterol* 2008; 43: 581-588
26 Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. *J Rheumatol Suppl* 1999; 56: 18-24
27 García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. *Lancet* 1994; 343: 769-772
28 Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman-Eszzuk S, Långström G, Naesdal J, Serrano P, Singh M, Skelly MM, Hawkey CJ. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. *Aliment Pharmacol Ther* 2005; 22: 795-801
29 Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 1995; 123: 241-249
30 Hudson N, Taha AS, Russell RI, Trye P, Cottrell J, Mann SG, Swanell AJ, Sturrock HD, Hawkey CJ. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. *Gastroenterology* 1997; 112: 1817-1822
31 Pilotto A, Franceschi M, Leandro G, Paris F, Cascavilla L, Longo MG, Niro V, Andrucci A, Scarcelli C, Di Mario F. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. *Aliment Pharmacol Ther* 2004; 20: 1091-1097
32 Mandal M, Rochon PA, Juvirtlink DN, Kopp A, Anderson GM, Naglie G, Austin PC, Laupacis A. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. *BMJ* 2002; 325: 624
33 Papatheodoridis GV, Archimandritis AJ. Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users. *World J Gastroenterol* 2005; 11: 3811-3816
34 Hunt RH, Bazzoli F. Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. *Aliment Pharmacol Ther* 2004; 19 Suppl 1: 9-16
35 Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, Chan HL, Sung JJ. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. *N Engl J Med* 2001; 344: 967-973
36 Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, Lau GK, Wong WM, Yuen MF, Chan AO, Lai CL, Wong J. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. *N Engl J Med* 2002; 346: 2033-2038
37 Malfhertheiner P, Mégraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report. *Aliment Pharmacol Ther* 2002; 16: 167-180

S-Editor Yang XC  L-Editor A  E-Editor Yang XC